Tearsheet
Investment Highlights Market Valuation Price Chart Return vs. Risk About VEEV Interactive Breakdown Better Bets vs. VEEV Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Veeva Systems (VEEV)

Market Price (10/25/2025): $293.13 | Market Cap: $47.9 Bil
Sector: Health Care | Industry: Health Care Technology

Veeva Systems (VEEV)

Market Price (10/25/2025): $293.13
Market Cap: $47.9 Bil
Sector: Health Care
Industry: Health Care Technology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13%		 Trading close to highs
Dist 52W High is -4.3%, Dist 3Y High is -4.3%		 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 60x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 36x, P/EPrice/Earnings or Price/(Net Income) is 59x
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 27%		 Weak multi-year price returns
2Y Excs Rtn is -15%		 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.8%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 45%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 45%		  
3 Low stock price volatility
Vol 12M is 36%		  
0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13%
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 27%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 45%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 45%
3 Low stock price volatility
Vol 12M is 36%
4 Trading close to highs
Dist 52W High is -4.3%, Dist 3Y High is -4.3%
5 Weak multi-year price returns
2Y Excs Rtn is -15%
6 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 60x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 36x, P/EPrice/Earnings or Price/(Net Income) is 59x
7 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.8%

Market Valuation & Key Metrics

VEEVS&P 500
REVENUE GROWTHGOOD
Rev LTM ($ Bil)3.0
Rev Chg Q16.7%6.4%
Rev Chg LTM15.3%5.3%
Rev Chg 3Y Avg14.1%5.4%
PROFITABILITYVERY GOOD
Op Inc LTM ($ Bil)0.8
CFO LTM ($ Bil)1.3
Net Inc LTM ($ Bil)0.8
Op Mgn LTM26.9%18.7%
CFO/Rev LTM45.5%20.4%
Net Inc Mgn27.3%12.7%
VALUATIONVERY HIGH
P/S16.13.3
P/CFO35.516.1
P/FCF35.520.9
P/E59.224.0
STABILITYVERY GOOD
Debt/Equity0.000.21
Cash/Assets0.800.07

VEEV Stock

   
   
   
   
   
   
   

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
VEEV Return94%-6%-37%19%9%39%102%
Peers Return37%-12%-39%11%-17%-4%-34%
S&P 500 Return16%27%-19%24%23%15%106%

Monthly Win Rates [3]
VEEV Win Rate67%58%33%50%58%67% 
Peers Win Rate40%22%18%33%18%52% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
VEEV Max Drawdown-14%-11%-41%-2%-11%-0% 
Peers Max Drawdown-7%-23%-41%-16%-31%-16% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: SDGR, TDOC, OMCL, CARL, HTFL. See VEEV Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/24/2025 (YTD)

How Low Can It Go

Unique KeyEventVEEVS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-55.7%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven125.7%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-26.7%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven36.4%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven29 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-26.5%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven36.1%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven32 days120 days

Compare to SDGR, TDOC, OMCL, CARL, HTFL


In The Past

Veeva Systems's stock fell -55.7% during the 2022 Inflation Shock from a high on 8/5/2021. A -55.7% loss requires a 125.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Veeva Systems (VEEV)

Better Bets than Veeva Systems (VEEV)

 VEEVBetter Performance than VEEV
MetricValueIndustry (Health Care Technology)
Rev Chg LTM15.3%TEM (59.8%), DOCS (19.4%), BTSG (28.1%), WAY (18.2%), WEAV (18.1%)
Rev Chg 3Y Avg14.1%DOCS (17.8%), BTSG (23.3%), PHR (22.6%), EVH (29.2%), WEAV (19.2%)
Op Mgn LTM26.9%DOCS (40.5%)
CFO/Rev LTM45.5%DOCS (49.9%)
FCF/Rev LTM45.5%DOCS (48.7%)
Total Yield1.7%DOCS (1.9%), SOLV (3.1%), GDRX (2.5%), HSTM (3.0%), SPOK (13.3%)
 VEEVBetter Performance than VEEV
MetricValueAll Other Sectors
Rev Chg LTM15.3%NVDA (71.6%), META (19.4%), AVGO (28.0%), NFLX (15.4%), PLTR (38.8%)
Rev Chg 3Y Avg14.1%NVDA (92.0%), AVGO (24.0%), PLTR (25.7%), GE (15.7%), TM (15.2%)
Op Mgn LTM26.9%NVDA (58.1%), AAPL (31.9%), MSFT (45.6%), GOOGL (32.7%), META (42.9%)
CFO/Rev LTM45.5%NVDA (46.6%), MSFT (48.3%), META (56.4%), V (60.4%), MA (53.3%)
FCF/Rev LTM45.5%V (56.8%), MA (49.2%), PLTR (49.7%), APP (53.7%), RY (131.7%)
Total Yield1.7%NVDA (1.9%), AAPL (2.9%), MSFT (3.2%), GOOGL (4.0%), AMZN (3.0%)
null

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Veeva Systems Earnings Notes  
2How Low Can Veeva Systems Stock Really Go?Return 
3VEEV At Price Support Zone, Right Time To Buy?Actionable 
4Wait For A Dip To Buy Veeva Systems StockBuy or Fear 
5As VEEV Falls 7.2% in a Day, DOCS's Story Stands OutCounter-Intuitive Comparisons 
6How Does Veeva Systems Stock Stack Up Against Its Peers?Peer Comparison 
7Better Bet Than VEEV Stock: Pay Less Than Veeva Systems To Get More From NVDA, LLY   
8Better Bet Than VEEV Stock: Pay Less Than Veeva Systems To Get More From LLY, BMRN   
9VEEV Dip Buy Analysis  
10Wait For A Dip To Buy Veeva Systems StockBuy or Fear 
11ARTICLES  
12VEEV Hits Key Support – Is This The Buying Opportunity? August 30th, 2025
13VEEV Dips 7.2% In One Day, Wait For A Dip To Buy The Stock August 29th, 2025
14VEEV’s 7.2% One Day Dip Begs The Question: Is DOCS Better Instead? August 29th, 2025
15VEEV Dropped 7.2% In A Day. Have You Fully Evaluated The Risk? August 29th, 2025
16Large Cap Stocks Trading At 52-Week High August 27th, 2025
Title
0DASHBOARDS
1VEEV Hits Key Support – Is This The Buying Opportunity?
2VEEV Dips 7.2% In One Day, Wait For A Dip To Buy The Stock
3VEEV’s 7.2% One Day Dip Begs The Question: Is DOCS Better Instead?
4VEEV Dropped 7.2% In A Day. Have You Fully Evaluated The Risk?
5Large Cap Stocks Trading At 52-Week High
6ARTICLES
7Veeva Systems Earnings Notes
8How Low Can Veeva Systems Stock Really Go?
9VEEV At Price Support Zone, Right Time To Buy?
10Wait For A Dip To Buy Veeva Systems Stock
11As VEEV Falls 7.2% in a Day, DOCS's Story Stands Out
12How Does Veeva Systems Stock Stack Up Against Its Peers?
13Better Bet Than VEEV Stock: Pay Less Than Veeva Systems To Get More From NVDA, LLY 
14Better Bet Than VEEV Stock: Pay Less Than Veeva Systems To Get More From LLY, BMRN 
15VEEV Dip Buy Analysis
16Wait For A Dip To Buy Veeva Systems Stock

Trade Ideas

Select past ideas related to VEEV. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		4.0%4.0%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.4%2.4%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.6%6.6%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		18.2%18.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		18.1%18.1%-8.0%
VEEV_12312022_Monopoly_xInd_xCD_Getting_Cheaper12312022VEEVVeeva SystemsMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		22.5%19.3%-1.9%
VEEV_6302022_Monopoly_xInd_xCD_Getting_Cheaper06302022VEEVVeeva SystemsMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-17.6%-0.2%-23.7%
VEEV_12312021_Monopoly_xInd_xCD_Getting_Cheaper12312021VEEVVeeva SystemsMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-20.1%-36.8%-40.9%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		4.0%4.0%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.4%2.4%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.6%6.6%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		18.2%18.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		18.1%18.1%-8.0%
VEEV_12312022_Monopoly_xInd_xCD_Getting_Cheaper12312022VEEVVeeva SystemsMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		22.5%19.3%-1.9%
VEEV_6302022_Monopoly_xInd_xCD_Getting_Cheaper06302022VEEVVeeva SystemsMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-17.6%-0.2%-23.7%
VEEV_12312021_Monopoly_xInd_xCD_Getting_Cheaper12312021VEEVVeeva SystemsMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-20.1%-36.8%-40.9%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1VICRVicor57.5%87.2%
2INBXInhibrx Biosciences53.8%272.0%
3CLBCore Laboratories48.7%-2.4%
4BALYBallys46.2%6.8%
5MOFGMidWestOne Financial43.2%39.2%
6NUVBNuvation Bio42.2%82.3%
7CLOVClover Health Investments41.0%21.3%
8CELCCelcuity36.6%442.2%
9WGOWinnebago Industries33.6%-12.7%
10GTXGarrett Motion33.3%91.3%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-45.4%8328.6%
2ITGRInteger-30.4%-45.0%
3METCRamaco Resources-23.8%244.9%
4WRLDWorld Acceptance-18.6%25.6%
5ASMAvino Silver & Gold Mines-18.2%450.5%
6SESSES AI-17.6%15.5%
7SMPLSimply Good Foods-17.5%-48.0%
8TNGXTango Therapeutics-17.0%142.6%
9OKLOOklo-16.7%540.8%
10LENZLENZ Therapeutics-16.4%10.7%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1WOLFWolfspeed1498.4%344.0%
2PRAXPraxis Precision Medicines253.2%126.1%
3NVTSNavitas Semiconductor116.1%294.1%
4SNDKSanDisk97.4% 
5UAMYUnited States Antimony90.3%578.5%
6GRALGRAIL85.2%400.8%
7BALYBallys82.9%6.8%
8ORKAOruka Therapeutics81.1%40.5%
9INBXInhibrx Biosciences79.9%272.0%
10CIFRCipher Mining77.2%345.3%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1VGVenture Global-35.7% 
2PMIPicard Medical-35.3%8328.6%
3SOCSable Offshore-33.7%-41.7%
4FWRDForward Air-28.9%-39.0%
5FLYFirefly Aerospace-28.5% 
6ITGRInteger-28.4%-45.0%
7USNAUsana Health Sciences-26.5%-42.0%
8HTZHertz Global-26.3%41.5%
9RCReady Capital-25.1%-50.3%
10ULHUniversal Logistics-24.8%-61.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1VICRVicor57.5%87.2%
2INBXInhibrx Biosciences53.8%272.0%
3CLBCore Laboratories48.7%-2.4%
4BALYBallys46.2%6.8%
5MOFGMidWestOne Financial43.2%39.2%
6NUVBNuvation Bio42.2%82.3%
7CLOVClover Health Investments41.0%21.3%
8CELCCelcuity36.6%442.2%
9WGOWinnebago Industries33.6%-12.7%
10GTXGarrett Motion33.3%91.3%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-45.4%8328.6%
2ITGRInteger-30.4%-45.0%
3METCRamaco Resources-23.8%244.9%
4WRLDWorld Acceptance-18.6%25.6%
5ASMAvino Silver & Gold Mines-18.2%450.5%
6SESSES AI-17.6%15.5%
7SMPLSimply Good Foods-17.5%-48.0%
8TNGXTango Therapeutics-17.0%142.6%
9OKLOOklo-16.7%540.8%
10LENZLENZ Therapeutics-16.4%10.7%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Veeva Systems

Financials

VEEVSDGRTDOCOMCLCARLHTFLMedian
NameVeeva Sy.Schrodin.Teladoc .Omnicell Carlsmed HeartFlow 
Mkt Price293.0222.529.4631.1013.4837.8726.81
Mkt Cap47.91.71.71.5--1.7
Rev LTM2,9682382,5421,15033139694
Op Inc LTM799-193-18315-24-61-43
FCF LTM1,3492415189-30-9057
FCF 3Y Avg1,108-95137123--130
CFO LTM1,34927303148-29-8588
CFO 3Y Avg1,108-86293180--237

Growth & Margins

VEEVSDGRTDOCOMCLCARLHTFLMedian
NameVeeva Sy.Schrodin.Teladoc .Omnicell Carlsmed HeartFlow 
Rev Chg LTM15.3%18.6%-2.6%6.4%--10.9%
Rev Chg 3Y Avg14.1%13.6%4.6%-2.6%--9.1%
Rev Chg Q16.7%15.7%-1.6%5.0%--10.3%
QoQ Delta Rev Chg LTM4.0%3.2%-0.4%1.2%--2.2%
Op Mgn LTM26.9%-81.1%-7.2%1.3%-71.4%-44.4%-25.8%
Op Mgn 3Y Avg22.5%-89.9%-8.1%-1.7%---4.9%
QoQ Delta Op Mgn LTM-0.0%2.5%0.1%0.4%--0.3%
CFO/Rev LTM45.5%11.6%11.9%12.9%-86.4%-61.5%11.7%
CFO/Rev 3Y Avg42.7%-44.1%11.4%15.7%--13.6%
FCF/Rev LTM45.5%10.2%5.9%7.8%-88.9%-65.0%6.9%
FCF/Rev 3Y Avg42.7%-48.4%5.3%10.7%--8.0%

Valuation

VEEVSDGRTDOCOMCLCARLHTFLMedian
NameVeeva Sy.Schrodin.Teladoc .Omnicell Carlsmed HeartFlow 
Mkt Cap47.91.71.71.5--1.7
P/S16.17.00.71.3--4.1
P/EBIT59.9-8.6-7.994.1--26.0
P/E59.2-9.1-8.063.0--25.6
P/CFO35.560.15.59.8--22.7
Total Yield1.7%-11.0%-12.5%1.6%---4.7%
Dividend Yield0.0%0.0%0.0%0.0%--0.0%
FCF Yield 3Y Avg3.1%-5.1%7.7%7.5%--5.3%
D/E0.00.10.60.3--0.2
Net D/E-0.1-0.20.2-0.0---0.1

Returns

VEEVSDGRTDOCOMCLCARLHTFLMedian
NameVeeva Sy.Schrodin.Teladoc .Omnicell Carlsmed HeartFlow 
1M Rtn5.4%18.2%12.6%0.7%-5.9%9.8%7.6%
3M Rtn0.9%1.3%15.4%10.0%-7.0%-1.3%
6M Rtn28.8%-14.9%31.4%0.5%--14.6%
12M Rtn37.8%27.2%10.0%-20.7%--18.6%
3Y Rtn75.8%-0.7%-64.6%-60.3%---30.5%
1M Excs Rtn1.8%15.5%16.2%-0.9%-1.1%8.8%5.3%
3M Excs Rtn-6.1%-5.7%9.1%1.0%-13.3%--5.7%
6M Excs Rtn5.9%-37.8%8.5%-22.5%---8.3%
12M Excs Rtn17.4%4.5%-11.1%-40.4%---3.3%
3Y Excs Rtn3.8%-78.7%-144.8%-142.7%---110.7%

Comparison Analyses

Financials

$ Mil | FY: 1/312026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q3
Period End7/31/20254/30/20251/31/202510/31/20247/31/20244/30/20241/31/202410/31/20237/31/20234/30/20231/31/202310/31/2022
Filing Date8/29/20256/2/20253/24/202512/9/20249/4/20246/4/20243/25/202412/7/20239/1/20236/2/20233/30/202312/7/2022
Key Financials Quarterly            
Total Revenue789759721699676650631617590526563552
Ebitda20624419819117816414413711269117129
Operating Income19623418818116615513512810462109121
Net Income200228196186171162147135112132189108
EPS1.231.401.201.151.061.000.920.840.700.821.200.70
Key Financials TTM            
Total Revenue TTM2,9682,8552,7472,6562,5742,4882,3642,2962,2322,1762,1552,077
Ebitda TTM839811731676622557462435426423488498
Operating Income TTM799770691638585523429403396393459470
Net Income TTM810781714666615556526567540519488396
Growth Rates Quarterly            
Total Revenue Growth16.7%16.7%14.3%13.4%14.6%23.6%11.9%11.6%10.5%4.2%16.0%16.0%
EBITDA Growth16.1%48.8%37.8%39.8%58.3%136.9%23.4%6.4%3.5%-48.7%-8.0%-7.9%
Operating Income Growth17.7%50.6%39.3%41.1%60.0%152.2%24.2%5.8%2.9%-51.8%-9.0%-8.5%
Net Income Growth17.1%41.2%32.7%37.5%53.2%22.9%-21.8%24.6%23.2%31.4%94.2%2.4%
Margins Quarterly            
EBITDA Margin26.1%32.1%27.5%27.4%26.3%25.2%22.8%22.2%19.0%13.1%20.7%23.3%
Operating Income Margin24.8%30.8%26.1%25.9%24.6%23.9%21.4%20.8%17.6%11.7%19.3%22.0%
Net Income Margin25.4%30.1%27.1%26.6%25.3%24.9%23.4%21.9%18.9%25.0%33.5%19.6%
Cash & Debt            
Total Cash6,4046,0685,1505,0634,8854,7654,0283,9423,8693,6153,1033,023
Total Debt857776725456565859586162
Net Debt / (Cash)-6,318-5,991-5,074-4,991-4,831-4,709-3,972-3,885-3,810-3,557-3,042-2,961
Cash Flows Quarterly            
FCF from Operations2388777016493764588326550663143
Cash Flows TTM            
FCF from Operations TTM1,3491,2041,0901,0789971,169911917977805780771
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC------------
Return on Invested Capital (ROIC) TTM            
ROIC TTM------------

Segment Financials

Revenue by Segment

$ Mil20252024202320222021
Subscription services1,9021,7331,4841,179896
Professional services462422367286208
Total2,3642,1551,8511,4651,104


Price Behavior

VEEV Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta0.970.930.890.610.670.89
Up Beta1.141.420.760.430.430.72
Down Beta-1.090.390.550.600.600.75
Up Capture191%87%88%98%113%120%
Bmk +ve Days13233574144420
Stock +ve Days12223062124368
Down Capture30%86%120%83%92%102%
Bmk -ve Days8192952107330
Stock -ve Days9203363126381

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date10152025
Short Interest: Shares Quantity4,503,453
Short Interest: % Change Since 9302025-15.5%
Average Daily Volume1,283,635
Days-to-Cover Short Interest3.51
Basic Shares Quantity163,496,000
Short % of Basic Shares2.8%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/27/2025-7.2%-8.0%-1.1%
5/28/202519.0%20.9%20.9%
3/5/20257.4%6.1%0.7%
11/8/20245.2%2.8%10.1%
8/28/20248.9%8.0%5.8%
5/30/2024-10.3%-4.7%-6.4%
2/29/2024-1.6%2.1%2.2%
11/9/2023-14.2%-8.9%-11.0%
...
SUMMARY STATS   
# Positive121413
# Negative121011
Median Positive7.9%5.1%8.5%
Median Negative-7.8%-9.2%-9.1%
Max Positive19.7%20.9%21.6%
Max Negative-16.2%-18.2%-17.3%

SEC Filings

Expand for More

Report DateFiling DateFiling
7312025829202510-Q 7/31/2025
4302025602202510-Q 4/30/2025
1312025324202510-K 1/31/2025
103120241209202410-Q 10/31/2024
7312024904202410-Q 7/31/2024
4302024604202410-Q 4/30/2024
1312024325202410-K 1/31/2024
103120231207202310-Q 10/31/2023
7312023901202310-Q 7/31/2023
4302023602202310-Q 4/30/2023
1312023330202310-K 1/31/2023
103120221207202210-Q 10/31/2022
7312022902202210-Q 7/31/2022
4302022603202210-Q 4/30/2022
1312022330202210-K 1/31/2022
103120211203202110-Q 10/31/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Faddis JonathanSVP, Gen. Counsel, Secretary7112025Sell285.62720205,6462,256,969Form
1Cabral Timothy S 6092025Sell289.7231591,2621,593,460Form
2Schwenger Thomas D.Pres. & Chief Customer Officer6022025Sell268.111,150308,3246,632,709Form
3Faddis JonathanSVP, Gen. Counsel, Secretary5052025Sell236.71833197,1791,854,623Form
4Schwenger Thomas D.Pres. & Chief Customer Officer4152025Sell220.76802177,0515,803,168Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.